Related Experiment Video
Updated: Aug 11, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Targeting angiogenesis in lung cancer
1Department of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-6307, USA. alam.sandler@vanderbilt.edu
Abstract:
The prognosis for the majority of patients with lung cancer remains poor, and treatment strategies including newer generation chemotherapeutics have not improved survival. New approaches are required to further improve patient outcome and survival. Recently, key molecules involved in signal transduction pathways that contribute to tumor growth have been identified as therapeutic targets, particularly molecules involved in cellular proliferation and angiogenesis. Novel therapeutics that specifically target angiogenesis have shown promise as single agents and in combination with standard chemotherapy. The results of recent studies validate the use of this class of targeted therapeutics as an important new treatment modality in cancer therapy. This review will focus on a discussion of antiangiogenic therapeutic monoclonal antibodies in development for the treatment of non-small cell lung cancer.
Insights
New antiangiogenic therapies targeting angiogenesis show promise for improving survival in non-small cell lung cancer patients. These targeted treatments represent a significant advancement in cancer therapy, offering new hope for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung cancer prognosis remains poor despite advancements in chemotherapy.
- Novel therapeutic targets are emerging from signal transduction pathways crucial for tumor growth.
- Angiogenesis, a key process in tumor development, is a focus for targeted therapies.
Purpose of the Study:
- To review antiangiogenic therapeutic monoclonal antibodies for non-small cell lung cancer (NSCLC).
- To discuss the potential of targeting angiogenesis in NSCLC treatment.
Main Methods:
- Review of recent studies on antiangiogenic therapies.
- Focus on monoclonal antibodies targeting angiogenesis.
- Discussion of combination therapies with standard chemotherapy.
Main Results:
- Antiangiogenic therapies show promise as single agents and in combination with chemotherapy.
- Targeted therapeutics demonstrate efficacy in recent studies.
- Monoclonal antibodies targeting angiogenesis are a validated treatment modality.
Conclusions:
- Antiangiogenic monoclonal antibodies are a promising new treatment for NSCLC.
- Targeting angiogenesis offers a novel approach to improve survival in lung cancer patients.
- Further development of these targeted therapies is warranted.
More Related Videos
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis